Table 2.

Clinical characteristics that affected progression-free survival 2 and overall survival 2 (N = 164).

Factors for PFS2	Ref	N	Hazard Ratio	95% CI		p-Value
ECOG PS 1	0	98				0.793
1–2		66	1.054	0.710	1.566
Endocrine resistance	De novo	70				0.778
Primary resistance		28	1.000	0.603	1.660
Secondary resistance		27	0.814	0.488	1.358
No resistance		39	0.817	0.511	1.307
Initial visceral metastasis	No	120				0.596
Yes		44	1.166	0.717	1.896
ER 2-driven BC 3		66				0.078
Yes	No	98	0.725	0.507	1.036
Disease progression site		53				0.039
Visceral organ	Other	64	1.169	0.773	1.768
Bone only		47	0.633	0.397	1.000
Second-line treatment	Capecitabine	47				0.031
Everolimus/exemestane		45	1.665	1.038	2.670
Other cytotoxic chemo		31	1.655	0.995	2.753
Fulvestrant		23	2.383	1.364	4.163
Clinical trials		18	1.713	0.904	3.246
Factors for OS2	Ref	N	Hazard Ratio	95% CI		p-Value
ECOG PS 1	0	98				0.720
1–2		66	0.897	0.494	1.628
Endocrine resistance	De novo	70				0.759
Primary resistance		28	0.770	0.373	1.593
Secondary resistance		27	0.687	0.297	1.590
No resistance		39	0.980	0.465	2.065
Initial visceral metastasis	No	120				0.039
Yes		44	2.097	1.039	4.234
ER 2-driven BC 3	No	66				0.019
Yes		98	0.525	0.306	0.901
Disease progression site	Other	53				0.026
Visceral organ		64	2.339	1.166	4.234
Bone only		47	0.967	0.461	2.027
Second-line treatment	Capecitabine	47				0.316
Everolimus/exemestane		45	0.890	0.421	1.878
Other cytotoxic chemo		31	1.253	0.600	2.617
Fulvestrant		23	0.669	0.274	1.631
Clinical trials		18	0.292	0.064	1.328
PFS2 4	≤5.2 months	88				<0.001
>5.2 months		76	0.323	0.188	0.589

¹: Eastern Cooperative Oncology Group Performance Status; ²: Estrogen receptor; ³: Breast cancer; ⁴: progression free survival 2.